Ihenetu Kenneth, Molleman Areles, Parsons Mike, Whelan Clifford
Department of Biosciences, CP Snow Building, Hatfield Campus, University of Hertfordshire, College Lane, UK.
Eur J Pharmacol. 2003 Mar 19;464(2-3):207-15. doi: 10.1016/s0014-2999(03)01379-7.
The effects of a range of cannabinoid receptor agonists and antagonists on phytohaemagglutinin-induced secretion of interleukin-2 from human peripheral blood mononuclear cells were investigated. The nonselective cannabinoid receptor agonist WIN55212-2 ((R)-(+)-2,3-dihydro-5-methyl-3-[4-morpholinylmethyl]pyrrolo[1,2,3-de]1,4-benzoxazin-6-yl methanone mesylate) and the selective cannabinoid CB(2) receptor agonist JWH 015 ((2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenylmethanone) inhibited phytohaemagglutinin (10 microg/ml)-induced release of interleukin-2 in a concentration-dependent manner (IC(1/2max), WIN55212-2=8.8 x 10(-7) M, 95% confidence limits (C.L.)=2.2 x 10(-7)-3.5 x 10(-6) M; JWH 015=1.8 x 10(-6) M, 95% C.L.=1.2 x 10(-6)-2.9 x 10(-6) M, n=5). The nonselective cannabinoid receptor agonists CP55,940 ((-)-3-[2-hydroxy-4-(1,1-dimethyl-hepthyl)-phenyl]4-[3-hydroxypropyl]cyclo-hexan-1-ol), Delta(9)-tetrahydrocannabinol and the selective cannabinoid CB(1) receptor agonist ACEA (arachidonoyl-2-chloroethylamide) had no significant (P>0.05) inhibitory effect on phytohaemagglutinin-induced release of interleukin-2. Dexamethasone significantly (P<0.05) inhibited phytohaemagglutinin-induced release of interleukin-2 in a concentration-dependent manner (IC(1/2max)=1.3 x 10(-8) M, 95% C.L.=1.4 x 10(-9)-3.2 x 10(-8) M). The cannabinoid CB(1) receptor antagonist SR141716A (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride) (10(-6) M) did not antagonise the inhibitory effect of WIN55212-2 whereas the cannabinoid CB(2) receptor antagonist SR144528 (N-(1,S)-endo-1,3,3-trimethyl bicyclo(2,2,1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide) antagonised the inhibitory effect of WIN55212-2 (pA(2)=6.3+/-0.1, n=5). In addition, CP55,940 (10(-6) M) and Delta(9)-tetrahydrocannabinol (10(-6) M) also antagonised the inhibitory effects of WIN55212-2 (pA(2)=6.1+/-0.1, n=5 and pA(2)=6.9+/-0.2, n=5). In summary, WIN55,212-2 and JWH 015 inhibited interleukin-2 release from human peripheral blood mononuclear cells via the cannabinoid CB(2) receptor. In contrast, CP55,940 and Delta(9)-tetrahydrocannabinol behaved as partial agonists/antagonists in these cells.
研究了一系列大麻素受体激动剂和拮抗剂对植物血凝素诱导的人外周血单核细胞白细胞介素 - 2分泌的影响。非选择性大麻素受体激动剂WIN55212 - 2((R) - (+) - [2,3 - 二氢 - 5 - 甲基 - 3 - [4 - 吗啉基甲基]吡咯并[1,2,3 - de]1,4 - 苯并恶嗪 - 6 - 基](1 - 萘基)甲酮甲磺酸盐)和选择性大麻素CB(2)受体激动剂JWH 015((2 - 甲基 - 1 - 丙基 - 1H - 吲哚 - 3 - 基) - 1 - 萘基甲酮)以浓度依赖性方式抑制植物血凝素(10μg/ml)诱导的白细胞介素 - 2释放(IC(1/2max),WIN55212 - 2 = 8.8×10( - 7)M,95%置信限(C.L.) = 2.2×10( - 7) - 3.5×10( - 6)M;JWH 015 = 1.8×10( - 6)M,95%C.L. = 1.2×10( - 6) - 2.9×10( - 6)M,n = 5)。非选择性大麻素受体激动剂CP55,940(( - ) - 3 - [2 - 羟基 - 4 - (1,1 - 二甲基 - 庚基) - 苯基]4 - [3 - 羟丙基]环己醇)、Δ(9) - 四氢大麻酚和选择性大麻素CB(1)受体激动剂ACEA(花生四烯酰 - 2 - 氯乙酰胺)对植物血凝素诱导的白细胞介素 - 2释放无显著(P>0.05)抑制作用。地塞米松以浓度依赖性方式显著(P<0.05)抑制植物血凝素诱导的白细胞介素 - 2释放(IC(1/2max) = 1.3×10( - 8)M,95%C.L. = 1.4×10( - 9) - 3.2×10( - 8)M)。大麻素CB(1)受体拮抗剂SR141716A(N - (哌啶 - 1 - 基) - 5 - (4 - 氯苯基) - 1 - (2,4 - 二氯苯基) - 4 - 甲基 - 1H - 吡唑 - 3 - 甲酰胺盐酸盐)(10( - 6)M)未拮抗WIN55212 - 2的抑制作用,而大麻素CB(2)受体拮抗剂SR144528(N - (1,S) - 内 - 1,3,3 - 三甲基双环(2,2,1)庚 - 2 - 基) - 5 - (4 - 氯 - 3 - 甲基苯基) - 1 - (4 - 甲基苄基) - 吡唑 - 3 - 甲酰胺)拮抗WIN55212 - 2的抑制作用(pA(2) = 6.3±0.1,n = 5)。此外,CP55,940(10( - 6)M)和Δ(9) - 四氢大麻酚(10( - 6)M)也拮抗WIN55212 -(pA(2) = 6.1±0.1,n = 5和pA(2) = 6.9±0.2,n = 5)。总之,WIN55,212 - 2和JWH 015通过大麻素CB(2)受体抑制人外周血单核细胞中白细胞介素 - 2的释放。相比之下,CP55,940和Δ(9) - 四氢大麻酚在这些细胞中表现为部分激动剂/拮抗剂。